- Home
- SWZ vs GNLX Comparison
SWZ vs GNLX Comparison
Compare SWZ & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWZ
- GNLX
- Stock Information
- Founded
- SWZ 1986
- GNLX 2001
- Country
- SWZ United States
- GNLX United States
- Employees
- SWZ N/A
- GNLX N/A
- Industry
- SWZ Finance Companies
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SWZ Finance
- GNLX Health Care
- Exchange
- SWZ Nasdaq
- GNLX Nasdaq
- Market Cap
- SWZ 103.5M
- GNLX 103.6M
- IPO Year
- SWZ N/A
- GNLX 2023
- Fundamental
- Price
- SWZ $7.54
- GNLX $2.27
- Analyst Decision
- SWZ
- GNLX Strong Buy
- Analyst Count
- SWZ 0
- GNLX 4
- Target Price
- SWZ N/A
- GNLX $18.25
- AVG Volume (30 Days)
- SWZ 14.2K
- GNLX 142.7K
- Earning Date
- SWZ 01-01-0001
- GNLX 11-14-2024
- Dividend Yield
- SWZ 6.59%
- GNLX N/A
- EPS Growth
- SWZ N/A
- GNLX N/A
- EPS
- SWZ N/A
- GNLX N/A
- Revenue
- SWZ N/A
- GNLX $8,000.00
- Revenue This Year
- SWZ N/A
- GNLX N/A
- Revenue Next Year
- SWZ N/A
- GNLX N/A
- P/E Ratio
- SWZ N/A
- GNLX N/A
- Revenue Growth
- SWZ N/A
- GNLX N/A
- 52 Week Low
- SWZ $7.12
- GNLX $1.60
- 52 Week High
- SWZ $8.57
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- SWZ 28.40
- GNLX 38.68
- Support Level
- SWZ $7.86
- GNLX $2.13
- Resistance Level
- SWZ $7.68
- GNLX $2.80
- Average True Range (ATR)
- SWZ 0.07
- GNLX 0.20
- MACD
- SWZ -0.02
- GNLX -0.04
- Stochastic Oscillator
- SWZ 10.02
- GNLX 14.21
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, and retail.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.